Tags

Type your tag names separated by a space and hit enter

The role of statins in managing diabetic dyslipidemia.
J Fam Pract. 2010 May; 59(5 Suppl):S23-9.JF

Abstract

The common lipid abnormalities associated with T2DM confer substantial CV risk. Statins are a safe and well-established treatment option for lowering this atherogenic burden and improving outcomes in this patient population. Nonetheless, many patients with T2DM are not receiving a statin, and even those who receive treatment may not be achieving recommended lipid targets. Strategies must be implemented to improve the quality of care for these patients who are at high risk for a primary or secondary CV event.

Links

Aggregator Full Text

Authors+Show Affiliations

Toth PP
Sterling Rock Falls Clinic, Ltd., Sterling, Illinois, USA.

MeSH

Cardiovascular DiseasesDiabetes Mellitus, Type 2DietDyslipidemiasHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLife StyleLipidsRandomized Controlled Trials as TopicWeight Loss

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20544054

Citation

Toth, Peter P.. "The Role of Statins in Managing Diabetic Dyslipidemia." The Journal of Family Practice, vol. 59, no. 5 Suppl, 2010, pp. S23-9.
Toth PP. The role of statins in managing diabetic dyslipidemia. J Fam Pract. 2010;59(5 Suppl):S23-9.
Toth, P. P. (2010). The role of statins in managing diabetic dyslipidemia. The Journal of Family Practice, 59(5 Suppl), S23-9.
Toth PP. The Role of Statins in Managing Diabetic Dyslipidemia. J Fam Pract. 2010;59(5 Suppl):S23-9. PubMed PMID: 20544054.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The role of statins in managing diabetic dyslipidemia. A1 - Toth,Peter P, PY - 2010/6/15/entrez PY - 2010/6/16/pubmed PY - 2010/7/16/medline SP - S23 EP - 9 JF - The Journal of family practice JO - J Fam Pract VL - 59 IS - 5 Suppl N2 - The common lipid abnormalities associated with T2DM confer substantial CV risk. Statins are a safe and well-established treatment option for lowering this atherogenic burden and improving outcomes in this patient population. Nonetheless, many patients with T2DM are not receiving a statin, and even those who receive treatment may not be achieving recommended lipid targets. Strategies must be implemented to improve the quality of care for these patients who are at high risk for a primary or secondary CV event. SN - 1533-7294 UR - https://www.unboundmedicine.com/medline/citation/20544054/The_role_of_statins_in_managing_diabetic_dyslipidemia_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=20544054.ui DB - PRIME DP - Unbound Medicine ER -